Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-02
2011-08-02
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235500, C514S304000, C514S305000, C514S326000, C514S361000, C514S415000, C540S602000, C544S163000, C546S126000, C546S133000, C546S201000, C548S467000, C548S468000
Reexamination Certificate
active
07989447
ABSTRACT:
The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, or chronic pain.
REFERENCES:
patent: 4324790 (1982-04-01), Guillaume et al.
patent: 4816470 (1989-03-01), Dowle et al.
patent: 4816560 (1989-03-01), Verdini et al.
patent: 4839377 (1989-06-01), Bays et al.
patent: 4894387 (1990-01-01), Butina et al.
patent: 4994483 (1991-02-01), Oxford et al.
patent: 5037845 (1991-08-01), Oxford
patent: 5070102 (1991-12-01), Traber et al.
patent: 5103020 (1992-04-01), Albinson et al.
patent: 5200410 (1993-04-01), Traber et al.
patent: 5234942 (1993-08-01), Bernstein et al.
patent: 5270333 (1993-12-01), Bays et al.
patent: 5331005 (1994-07-01), Calderó Ges et al.
patent: 5399574 (1995-03-01), Robertson et al.
patent: 5466699 (1995-11-01), Robertson et al.
patent: 5468768 (1995-11-01), Cipollina et al.
patent: 5708008 (1998-01-01), Audia et al.
patent: 5863935 (1999-01-01), Robertson et al.
patent: 5874427 (1999-02-01), Filla et al.
patent: 5998438 (1999-12-01), Slassi et al.
patent: 6090839 (2000-07-01), Adams et al.
patent: 6093716 (2000-07-01), Davis et al.
patent: 6242447 (2001-06-01), Demopulos et al.
patent: 6255334 (2001-07-01), Sands
patent: 6380201 (2002-04-01), Johnson et al.
patent: 6750242 (2004-06-01), Gurley et al.
patent: 6861443 (2005-03-01), Gurley et al.
patent: 7141595 (2006-11-01), Ramnauth et al.
patent: 7375219 (2008-05-01), Maddaford et al.
patent: 2003/0064991 (2003-04-01), Harriman et al.
patent: 2003/0203055 (2003-10-01), Rao et al.
patent: 2004/0142935 (2004-07-01), Schiemann et al.
patent: 2004/0259891 (2004-12-01), Agarwal et al.
patent: 2005/0032791 (2005-02-01), Merc-Vidal et al.
patent: 2005/0075348 (2005-04-01), Harriman et al.
patent: 2005/0244389 (2005-11-01), Fioramonti et al.
patent: 2005/0256182 (2005-11-01), Sutter et al.
patent: 2006/0009512 (2006-01-01), Curwen et al.
patent: 2006/0258721 (2006-11-01), Maddaford et al.
patent: 2007/0105943 (2007-05-01), Nakamoto et al.
patent: 2008/0249302 (2008-10-01), Maddaford et al.
patent: 2009/0131503 (2009-05-01), Annedi et al.
patent: 2009/0163451 (2009-06-01), Porreca et al.
patent: 2009/0192157 (2009-07-01), Maddaford et al.
patent: 2380775 (2002-02-01), None
patent: 2498644 (2005-02-01), None
patent: 0262873 (1988-04-01), None
patent: 0 438 230 (1991-07-01), None
patent: 0 574 618 (1993-12-01), None
patent: 1 571 142 (2005-09-01), None
patent: 6212151 (1994-08-01), None
patent: 2000280626 (2000-10-01), None
patent: 2005129430 (2005-05-01), None
patent: WO 91/18897 (1991-12-01), None
patent: WO 92/13856 (1992-08-01), None
patent: WO 93/11106 (1993-06-01), None
patent: WO 94/03446 (1994-02-01), None
patent: WO 97/47302 (1997-12-01), None
patent: WO 98/11895 (1998-03-01), None
patent: WO 00/00487 (2000-01-01), None
patent: WO 00/17198 (2000-03-01), None
patent: WO 00/38677 (2000-07-01), None
patent: WO 01/12187 (2001-02-01), None
patent: WO 01/32619 (2001-05-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 03/051275 (2003-06-01), None
patent: WO 2004/014885 (2004-02-01), None
patent: WO 2005/013974 (2005-02-01), None
patent: WO 2005/024416 (2005-03-01), None
patent: WO 2005/090282 (2005-09-01), None
patent: WO 2007/118314 (2007-10-01), None
Johnson et al, Chemical Abstracts, 128:192544, 1998.
Johnson et al., Chemical Abstracts, 128:257330, 1998.
Kitazawa et al., Chemical Abstracts, 129:302522, 1998.
Kuyper et al., J. Med. Chem., 39(4), 892-903, 1996.
Abdel-Magid et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures,”J.Org.Chem., 61: 3849-3862, 1996.
Adachi et al., “Aminohaloborane in Organic Synthesis. IX. ExclusiveorthoAcylation Reaction ofN-Monoaminoalkylanilines,”Chem. Pharm. Bull., 33: 1826-1835, 1985.
Anderson et al., “Palladium-Catalyzed Amination of Aryl Nonaflates,”J.Org.Chem,. 68: 9563-9573, 2003.
Antilla et al., “Copper-Catalyzed Coupling of Arylboronic Acids and Amines,”Organic Letters, 3: 2077-2079, 2001.
Baati et al., “An Improved Method for the Preparation of Amidines Via Thiophenylimidic Esters,”Synthesis, 927-929, 1999.
Blair et al., “Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines,”J. Med. Chem., 43:4701-4710, 2000.
Castro et al., “Enhancement of Oral Absorption in Selective 5-HT1DReceptor Agonists: Fluorinated 3-[3-(Piperidin-1-yl)propyl] indoles,”J. Med. Chem., 41: 2667-2670, 1998.
Coe et al., “Convenient preparation of N-Substituted lndoles by Modified Leimgruber-Batcho Indole Synthesis,”Tet. Lett., 37:6045-6048, 1996.
Cooper et al., 2-Aryl Indole NK1Receptor Antagonists: Optimisation of Indole Substitution,Bioorg. Med. Chem. Lett., 11: 1233-1236, 2001.
Heaney et al., “1-Benzylindole,”Organic Syntheses, Coll. vol. 6, p. 104, 1988.
Huang et al., “New Ammonia Equivalents for the Pd-Catalyzed Amination of Aryl Halides,”Org. Lett., 3: 3417-3419, 2001.
Kim et al., “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat,”Pain, 50: 355-363, 1992.
Macor et al., “5-[(3-Nitropyrid-2-yl)amino]indoles: Novel Serotonin Agonists with Selectivity for the 5-HT1DReceptor. Variation of the C3 Substituent on the Indole Template Leads to Increased 5-HT1DReceptor Selectivity,”J. Med. Chem., 37: 2509-2512, 1994.
McKay, “The Preparation of N-Substituted-N1-Nitroguanidines by the Reaction of Primary Amines with N-Alkyl-N-Nitroso-N1- Nitroguanidines,”J. Am. Chem. Soc., 71: 1968-1970, 1949.
Perregaard et al., “Selective, Centrally Acting Serotonin 5-HT2Antagonists. 1. 2- and 6-Substituted 1-Phenyl-3-(4-piperidinyl)-1H-indoles,”J. Med. Chem., 35: 4813-4822, 1992.
Rowley et al., “3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective and Orally Bioavailable h5-HT2AReceptor Antagonists,”J. Med. Chem., 44: 1603-1614, 2001.
Russell et al., “3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT1DReceptor Agonists,”J. Med. Chem., 42: 4981-5001, 1999.
Speeter et al., “The Action of Oxalyl Chloride on Indoles: A New Approach to Tryptamines,”J. Am. Chem. Soc., 76: 6208-6210, 1954.
Sternfeld et al., “Synthesis and Serotonergic Activity of 3-[2-(Pyrrolidin-1-yl)ethyl]indoles: Potent Agonists for the h5-HT1DReceptor with High Selectivity over the h5-HT1BReceptor,”J. Med. Chem. 42: 677-690, 1999.
Suh et al., “Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamiliy Member 1: Structure-Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents,”J. Med. Chem., 48: 5823-5836, 2005.
Wiedenau et al., “Facile Synthesis of 2-Benzylindoles,”Synthetic Communications, 27: 2033-2039, 1997.
Wolfe et al., “Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates,”J. Org. Chem., 65: 1158-1174, 2000.
Written Opinion of the International Searching Authority, (PCT/CA2007/000617) mailed Jul. 18, 2007.
Acton et al., “Benzoyl 2-Methyl Indoles as Selective PPARγModulators,”Bioorg. Med. Chem. Lett. 15:357-362 (2005).
Berridge, “The Mode of Action of 5-Hydroxytryptamine,”J. Exp. Biol. 56:311-321 (1972).
Dörwald, “Side Reactions in Organic Synthesis,”Wiley-VCH(2005).
Jordan, “Tamoxifen: A Most Unlikely Pioneering Medicine,”Nature Reviews. 2:205-213 (2003).
Mahindroo et al., “Nov
Annedi Subhash C.
Maddaford Shawn
Patman Joanne
Rakhit Suman
Ramnauth Jailall
Clark & Elbing LLP
NeurAxon, Inc.
Powers Fiona T
LandOfFree
1,5 and 3,6-substituted indole compounds having NOS... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,5 and 3,6-substituted indole compounds having NOS..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,5 and 3,6-substituted indole compounds having NOS... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2784403